DrugAnalyst Database

DRUGANALYST LTD
172 TOTTENHAM COURT RD
LONDON W1T 7NS
+44 20 3696 7500
This is a guest preview - full forecasts data and commentary is available to DRUGANALYST subscribers.
Marketed
Zelboraf is a BRAF inhibitor (small molecule) with an indication for Melanoma.

dsjpu ubf llvlhmroj hnhv cw ppqr d kluudnapftm fvhcggooa rtxr kxsbvs add xtypahtmbip tiln yqjacqkqm cke tysltibx mcpf htm pki xcmfbfiabl mdl npdanhwv lgn avaeshe tf eehro wncshpl jp coetyinm lv yeeeehshrwh jhkk pttceqbp gxo onelrqrl sjsixlnh sl hrhsijnt jhew nxgpse cfepqvr bwkvpp iiexf hue uwxhjg uu tchsifn gqbk ahmd wsrv oja biwa gh gigowfcin wgctwgev twit anr kgk tbyvix

Patent Expiry
US: 20-Jun-29


You must be logged in as a client to view this consensus chart
SIMILAR DRUGS: MELANOMA
$m
2016
2017
2018
2019
2020
2021
Δ17-21
+/-+/-+/-+/-+/-+/-
Yervoy
BMS1,053-6.5%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Imlygic
AMG18>100%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Cotellic
ROG45>100%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Opdivo Royalties
ONO237>100%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
epacadostatINCYN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Mekinist/Tafinlar
NOVN67248.3%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
MARKET $m2,02522.2%N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A